Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Microenvironment
Published in: Cancer Microenvironment 3/2015

01-12-2015

IL-1 in Colon Inflammation, Colon Carcinogenesis and Invasiveness of Colon Cancer

Authors: Elena Voronov, Ron N. Apte

Published in: Cancer Microenvironment | Issue 3/2015

Login to get access

Abstract

Interleukin-1 (IL-1) is a major “alarm” upstream pro-inflammatory cytokine that mainly acts by inducing cascades of cytokine and inflammation-promoting mediators. In the tumor arena, IL-1 is produced by both malignant and microenvironmental cells. IL-1α and IL-1β are the major agonists of IL-1, while IL-1Ra is a physiological inhibitor of pre-formed IL-1. IL-1α and IL-1β differ in their compartmentalization and in the producing cells. IL-1β is only active in its inflammasome dependent processed and secreted form and has been considered as the major mediator of inflammation. On the other hand, IL-1α is mainly cell-associated in tissue resident cells, being also active in its precursor form. The role of the IL-1 molecules in the unique microenvironment in the colon is largely unknown. Here, we described the role of IL-1α and IL-1β in colon homeostasis, colon inflammation, colon carcinogenesis and invasiveness of colorectal cancer. Understanding of the integrative role of IL-1α and IL-1β in these processes will facilitate the application of novel IL-1 modulating approaches.
Literature
1.
Pancione M, Giordano G, Remo A, Febbraro A, Sabatino L, Manfrin E, Ceccarelli M, Colantuoni V (2014) Immune escape mechanisms in colorectal cancer pathogenesis and liver metastasis. J Immunol Res 2014:686879PubMedPubMedCentralCrossRef
2.
Westbrook AM, Szakmary A, Schiestl RH (2010) Mechanisms of intestinal inflammation and development of associated cancers: lessons learned from mouse models. Mutat Res 705:40–59PubMedPubMedCentralCrossRef
3.
4.
5.
Vendramini-Costa DB, Carvalho JE (2012) Molecular link mechanisms between inflammation and cancer. Curr Pharm Des 18:3831–3852PubMedCrossRef
6.
Engel MA, Neurath MF (2010) New pathophysiological insights and modern treatment of IBD. J Gastroenterol 45:571–583PubMedCrossRef
7.
Hamilton MJ, Snapper SB, Blumberg RS (2012) Update on biologic pathways in inflammatory bowel disease and their therapeutic relevance. J Gastroenterol 47:1–8PubMedPubMedCentralCrossRef
8.
9.
Tlaskalova-Hogenova H, Stepankova R, Kozakova H, Hudcovic T, Vannucci L, Tuckova L, Rossmann P, Hrncir T, Kverka M, Zakostelska Z, Klimesova K, Pribylova J, Bartova J, Sanchez D, Fundova P, Borovska D, Srutkova D, Zidek Z, Schwarzer M, Drastich P, Funda DP (2011) The role of gut microbiota (commensal bacteria) and the mucosal barrier in the pathogenesis of inflammatory and autoimmune diseases and cancer: contribution of germ-free and gnotobiotic animal models of human diseases. Cell Mol Immunol 8:110–120PubMedPubMedCentralCrossRef
10.
Ullman TA, Itzkowitz SH (2011) Intestinal inflammation and cancer. Gastroenterology 140:1807–1816PubMedCrossRef
11.
Yang VW, Lewis J, Wang TC, Rustgi AK (2010) Colon cancer: an update and future directions. Gastroenterology 138:2027–2028PubMedCrossRef
12.
13.
14.
15.
Abraham C, Medzhitov R (2011) Interactions between the host innate immune system and microbes in inflammatory bowel disease. Gastroenterology 140:1729–1737PubMedPubMedCentralCrossRef
16.
17.
MacDonald TT, Monteleone I, Fantini MC, Monteleone G (2011) Regulation of homeostasis and inflammation in the intestine. Gastroenterology 140:1768–1775PubMedCrossRef
18.
Lebeer S, Vanderleyden J, De Keersmaecker SC (2010) Host interactions of probiotic bacterial surface molecules: comparison with commensals and pathogens. Nat Rev Microbiol 8:171–184PubMedCrossRef
19.
Lotz M, Gutle D, Walther S, Menard S, Bogdan C, Hornef MW (2006) Postnatal acquisition of endotoxin tolerance in intestinal epithelial cells. J Exp Med 203:973–984PubMedPubMedCentralCrossRef
20.
Smythies LE, Sellers M, Clements RH, Mosteller-Barnum M, Meng G, Benjamin WH, Orenstein JM, Smith PD (2005) Human intestinal macrophages display profound inflammatory anergy despite avid phagocytic and bacteriocidal activity. J Clin Invest 115:66–75PubMedPubMedCentralCrossRef
21.
Uematsu S, Akira S (2008) Toll-Like receptors (TLRs) and their ligands. Handb Exp Pharmacol 1–20
22.
Murai M, Turovskaya O, Kim G, Madan R, Karp CL, Cheroutre H, Kronenberg M (2009) Interleukin 10 acts on regulatory T cells to maintain expression of the transcription factor Foxp3 and suppressive function in mice with colitis. Nat Immunol 10:1178–1184PubMedPubMedCentralCrossRef
23.
24.
Cario E (2010) Heads up! How the intestinal epithelium safeguards mucosal barrier immunity through the inflammasome and beyond. Curr Opin Gastroenterol 26:583–590PubMedCrossRef
25.
26.
Harrison OJ, Maloy KJ (2011) Innate immune activation in intestinal homeostasis. J Innate Immunity 3:585–593CrossRef
27.
Maloy KJ, Powrie F (2011) Intestinal homeostasis and its breakdown in inflammatory bowel disease. Nature 474:298–306PubMedCrossRef
28.
Rakoff-Nahoum S, Paglino J, Eslami-Varzaneh F, Edberg S, Medzhitov R (2004) Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell 118:229–241PubMedCrossRef
29.
Saleh M, Trinchieri G (2010) Innate immune mechanisms of colitis and colitis-associated colorectal cancer. Nat Rev Immunol 11:9–20PubMedCrossRef
30.
31.
Terzic J, Grivennikov S, Karin E, Karin M (2010) Inflammation and colon cancer. Gastroenterology 138(2101–2114), e2105
32.
Xavier RJ, Podolsky DK (2007) Unravelling the pathogenesis of inflammatory bowel disease. Nature 448:427–434PubMedCrossRef
33.
Apte RN, Voronov E (2008) Is interleukin-1 a good or bad ‘guy’ in tumor immunobiology and immunotherapy? Immunol Rev 222:222–241PubMedCrossRef
34.
Dinarello CA (2009) Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol 27:519–550PubMedCrossRef
35.
Dinarello CA (2011) A clinical perspective of IL-1beta as the gatekeeper of inflammation. Eur J Immunol 41:1203–1217PubMedCrossRef
36.
Gabay C, Lamacchia C, Palmer G (2010) IL-1 pathways in inflammation and human diseases. Nat Rev Rheumatol 6:232–241PubMedCrossRef
37.
Garlanda C, Anders HJ, Mantovani A (2009) TIR8/SIGIRR: an IL-1R/TLR family member with regulatory functions in inflammation and T cell polarization. Trends Immunol 30:439–446PubMedCrossRef
38.
O’Neill LA (2008) The interleukin-1 receptor/Toll-like receptor superfamily: 10 years of progress. Immunol Rev 226:10–18PubMedCrossRef
39.
40.
41.
Palm NW, Medzhitov R (2009) Pattern recognition receptors and control of adaptive immunity. Immunol Rev 227:221–233PubMedCrossRef
42.
43.
Carta S, Castellani P, Delfino L, Tassi S, Vene R, Rubartelli A (2009) DAMPs and inflammatory processes: the role of redox in the different outcomes. J Leukoc Biol 86:549–555PubMedCrossRef
44.
45.
Srikrishna G, Freeze HH (2009) Endogenous damage-associated molecular pattern molecules at the crossroads of inflammation and cancer. Neoplasia 11:615–628PubMedPubMedCentralCrossRef
46.
47.
Vanaja SK, Rathinam VA, Fitzgerald KA (2015) Mechanisms of inflammasome activation: recent advances and novel insights. Trends Cell Biol 25:308–315PubMedCrossRef
48.
49.
Franchi L, Eigenbrod T, Munoz-Planillo R, Nunez G (2009) The inflammasome: a caspase-1-activation platform that regulates immune responses and disease pathogenesis. Nat Immunol 10:241–247PubMedPubMedCentralCrossRef
50.
51.
Martinon F, Mayor A, Tschopp J (2009) The inflammasomes: guardians of the body. Annu Rev Immunol 27:229–265PubMedCrossRef
52.
53.
Vermeire S, Van Assche G, Rutgeerts P (2010) Inflammatory bowel disease and colitis: new concepts from the bench and the clinic. Curr Opin Gastroenterol 27:32–37CrossRef
54.
55.
56.
Strowig T, Henao-Mejia J, Elinav E, Flavell R (2012) Inflammasomes in health and disease. Nature 481:278–286PubMedCrossRef
57.
Zitvogel L, Kepp O, Galluzzi L, Kroemer G (2012) Inflammasomes in carcinogenesis and anticancer immune responses. Nat Immunol 13:343–351PubMedCrossRef
58.
59.
60.
Fettelschoss A, Kistowska M, LeibundGut-Landmann S, Beer HD, Johansen P, Senti G, Contassot E, Bachmann MF, French LE, Oxenius A, Kundig TM (2011) Inflammasome activation and IL-1beta target IL-1alpha for secretion as opposed to surface expression. Proc Natl Acad Sci U S A 108:18055–18060PubMedPubMedCentralCrossRef
61.
62.
Keller M, Ruegg A, Werner S, Beer HD (2008) Active caspase-1 is a regulator of unconventional protein secretion. Cell 132:818–831PubMedCrossRef
63.
64.
Hacham M, Argov S, White RM, Segal S, Apte RN (2002) Different patterns of interleukin-1alpha and interleukin-1beta expression in organs of normal young and old mice. Eur Cytokine Netw 13:55–65PubMed
65.
Hacham M, Cristal N, White RM, Segal S, Apte RN (1996) Complementary organ expression of IL-1 vs. IL-6 and CSF-1 activities in normal and LPS-injected mice. Cytokine 8:21–31PubMedCrossRef
66.
67.
68.
69.
Cohen I, Rider P, Carmi Y, Braiman A, Dotan S, White MR, Voronov E, Martin MU, Dinarello CA, Apte RN (2010) Differential release of chromatin-bound IL-1alpha discriminates between necrotic and apoptotic cell death by the ability to induce sterile inflammation. Proc Natl Acad Sci U S A 107:2574–2579PubMedPubMedCentralCrossRef
70.
71.
Rider P, Carmi Y, Guttman O, Braiman A, Cohen I, Voronov E, White MR, Dinarello CA, Apte RN (2011) IL-1alpha and IL-1beta recruit different myeloid cells and promote different stages of sterile inflammation. J Immunol 187:4835–4843PubMedCrossRef
72.
73.
74.
Rider P, Kaplanov I, Romzova M, Bernardis L, Braiman A, Voronov E, Apte RN (2012) The transcription of the alarmin cytokine interleukin-1 alpha is controlled by hypoxia inducible factors 1 and 2 alpha in hypoxic cells. Front Immunol 3:290PubMedPubMedCentralCrossRef
75.
Zheng Y, Humphry M, Maguire JJ, Bennett MR, Clarke MC (2013) Intracellular interleukin-1 receptor 2 binding prevents cleavage and activity of interleukin-1alpha, controlling necrosis-induced sterile inflammation. Immunity 38:285–295PubMedPubMedCentralCrossRef
76.
77.
Kim B, Lee Y, Kim E, Kwak A, Ryoo S, Bae SH, Azam T, Kim S, Dinarello CA (2013) The Interleukin-1alpha Precursor is Biologically Active and is Likely a Key Alarmin in the IL-1 Family of Cytokines. Front Immunol 4:391PubMedPubMedCentral
78.
Apte RN, Dotan S, Elkabets M, White MR, Reich E, Carmi Y, Song X, Dvozkin T, Krelin Y, Voronov E (2006) The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions. Cancer Metastasis Rev 25:387–408PubMedCrossRef
79.
Apte RN, Krelin Y, Song X, Dotan S, Recih E, Elkabets M, Carmi Y, Dvorkin T, White RM, Gayvoronsky L, Segal S, Voronov E (2006) Effects of micro-environment- and malignant cell-derived interleukin-1 in carcinogenesis, tumour invasiveness and tumour-host interactions. Eur J Cancer 42:751–759PubMedCrossRef
80.
Voronov E, Dotan S, Krelin Y, Song X, Elkabets M, Carmi Y, Rider P, Idan C, Romzova M, Kaplanov I, Apte RN (2013) Unique versus redundant functions of IL-1alpha and IL-1beta in the tumor microenvironment. Front Immunol 4:177PubMedPubMedCentralCrossRef
81.
Krelin Y, Voronov E, Dotan S, Elkabets M, Reich E, Fogel M, Huszar M, Iwakura Y, Segal S, Dinarello CA, Apte RN (2007) Interleukin-1beta-driven inflammation promotes the development and invasiveness of chemical carcinogen-induced tumors. Cancer Res 67:1062–1071PubMedCrossRef
82.
Smyth MJ, Dunn GP, Schreiber RD (2006) Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv Immunol 90:1–50PubMedCrossRef
83.
Elkabets M, Krelin Y, Dotan S, Cerwenka A, Porgador A, Lichtenstein RG, White MR, Zoller M, Iwakura Y, Dinarello CA, Voronov E, Apte RN (2009) Host-derived interleukin-1alpha is important in determining the immunogenicity of 3-methylcholantrene tumor cells. J Immunol 182:4874–4881PubMedCrossRef
84.
Chow MT, Moller A, Smyth MJ (2012) Inflammation and immune surveillance in cancer. Semin Cancer Biol 22:23–32PubMedCrossRef
85.
Arwert EN, Lal R, Quist S, Rosewell I, van Rooijen N, Watt FM (2010) Tumor formation initiated by nondividing epidermal cells via an inflammatory infiltrate. Proc Natl Acad Sci U S A 107:19903–19908PubMedPubMedCentralCrossRef
86.
Cataisson C, Salcedo R, Hakim S, Moffitt BA, Wright L, Yi M, Stephens R, Dai RM, Lyakh L, Schenten D, Yuspa HS, Trinchieri G (2012) IL-1R-MyD88 signaling in keratinocyte transformation and carcinogenesis. J Exp Med 209:1689–1702PubMedPubMedCentralCrossRef
87.
Ling J, Kang Y, Zhao R, Xia Q, Lee DF, Chang Z, Li J, Peng B, Fleming JB, Wang H, Liu J, Lemischka IR, Hung MC, Chiao PJ (2012) KrasG12D-induced IKK2/beta/NF-kappaB activation by IL-1alpha and p62 feedforward loops is required for development of pancreatic ductal adenocarcinoma. Cancer Cell 21:105–120PubMedPubMedCentralCrossRef
88.
Tu S, Bhagat G, Cui G, Takaishi S, Kurt-Jones EA, Rickman B, Betz KS, Penz-Oesterreicher M, Bjorkdahl O, Fox JG, Wang TC (2008) Overexpression of interleukin-1beta induces gastric inflammation and cancer and mobilizes myeloid-derived suppressor cells in mice. Cancer Cell 14:408–419PubMedPubMedCentralCrossRef
89.
Elkabets M, Ribeiro VSG, Dinarello CA, Ostrand-Rosenberg S, Di Santo J, Apte RN, Vosshenrich CAJ (2010) IL-1β regulates a novel myeloid-derived suppressor cell subset that impairs NK cell development and function. Eur J Immunol 40
90.
Song X, Krelin Y, Dvorkin T, Bjorkdahl O, Segal S, Dinarello CA, Voronov E, Apte RN (2005) CD11b+/Gr-1+ Immature Myeloid Cells Mediate Suppression of T Cells in Mice Bearing Tumors of IL-1{beta}-Secreting Cells. J Immunol 175:8200–8208PubMedCrossRef
91.
Dvorkin T, Song X, Argov S, White RM, Zoller M, Segal S, Dinarello CA, Voronov E, Apte RN (2006) Immune phenomena involved in the in vivo regression of fibrosarcoma cells expressing cell-associated IL-1{alpha}. J Leukoc Biol 80:96–106PubMedCrossRef
92.
Song X, Voronov E, Dvorkin T, Fima E, Cagnano E, Benharroch D, Shendler Y, Bjorkdahl O, Segal S, Dinarello CA, Apte RN (2003) Differential effects of IL-1 alpha and IL-1 beta on tumorigenicity patterns and invasiveness. J Immunol 171:6448–6456PubMedCrossRef
93.
el-Shami KM, Tzehoval E, Vadai E, Feldman M, Eisenbach L (1999) Induction of antitumor immunity with modified autologous cells expressing membrane-bound murine cytokines. J Interf Cytokine Res: Off J Int Soc Interf Cytokine Res 19:1391–1401CrossRef
94.
Marr RA, Addison CL, Snider D, Muller WJ, Gauldie J, Graham FL (1997) Tumour immunotherapy using an adenoviral vector expressing a membrane-bound mutant of murine TNF alpha. Gene Ther 4:1181–1188PubMedCrossRef
95.
Soo Hoo W, Lundeen KA, Kohrumel JR, Pham NL, Brostoff SW, Bartholomew RM, Carlo DJ (1999) Tumor cell surface expression of granulocyte-macrophage colony-stimulating factor elicits antitumor immunity and protects from tumor challenge in the P815 mouse mastocytoma tumor model. J Immunol 162:7343–7349PubMed
96.
Marhaba R, Nazarenko I, Knofler D, Reich E, Voronov E, Vitacolonna M, Hildebrand D, Elter E, Apte RN, Zoller M (2008) Opposing effects of fibrosarcoma cell-derived IL-1alpha and IL-1beta on immune response induction. Int J Cancer 123:134–145PubMedCrossRef
97.
Nazarenko I, Marhaba R, Reich E, Voronov E, Vitacolonna M, Hildebrand D, Elter E, Rajasagi M, Apte RN, Zoller M (2008) Tumorigenicity of IL-1alpha- and IL-1beta-deficient fibrosarcoma cells. Neoplasia 10:549–562PubMedPubMedCentralCrossRef
98.
Voronov E, Reich E, Dotan S, Dransh P, Cohen I, Huszar M, Fogel M, Kleinman HK, White RM, Apte RN (2009) Effects of IL-1 molecules on growth patterns of 3-MCA-induced cell lines: An interplay between immunogenicity and invasive potential. J Immunotoxicol
99.
Carmi Y, Rinott G, Dotan S, Elkabets M, Rider P, Voronov E, Apte RN (2011) Microenvironment-derived IL-1 and IL-17 interact in the control of lung metastasis. J Immunol 186:3462–3471PubMedCrossRef
100.
Berglund M, Melgar S, Kobayashi KS, Flavell RA, Hornquist EH, Hultgren OH (2010) IL-1 receptor-associated kinase M downregulates DSS-induced colitis. Inflamm Bowel Dis 16:1778–1786PubMedCrossRef
101.
Casini-Raggi V, Kam L, Chong YJ, Fiocchi C, Pizarro TT, Cominelli F (1995) Mucosal imbalance of IL-1 and IL-1 receptor antagonist in inflammatory bowel disease. A novel mechanism of chronic intestinal inflammation. J Immunol 154:2434–2440PubMed
102.
Cominelli F, Nast CC, Clark BD, Schindler R, Lierena R, Eysselein VE, Thompson RC, Dinarello CA (1990) Interleukin 1 (IL-1) gene expression, synthesis, and effect of specific IL-1 receptor blockade in rabbit immune complex colitis. J Clin Invest 86:972–980PubMedPubMedCentralCrossRef
103.
Kaczmarek E, Banasiewicz T, Seraszek-Jaros A, Krokowicz P, Grochowalski M, Majewski P, Zurawski J, Paszkowski J, Drews M (2014) Digital image analysis of inflammation markers in colorectal mucosa by using a spatial visualization method. Pathol Res Pract 210:147–154PubMedCrossRef
104.
105.
106.
107.
Mahida YR, Wu K, Jewell DP (1989) Enhanced production of interleukin 1-beta by mononuclear cells isolated from mucosa with active ulcerative colitis of Crohn’s disease. Gut 30:835–838PubMedPubMedCentralCrossRef
108.
Stronati L, Negroni A, Pierdomenico M, D’Ottavio C, Tirindelli D, Di Nardo G, Oliva S, Viola F, Cucchiara S (2010) Altered expression of innate immunity genes in different intestinal sites of children with ulcerative colitis. Dig Liver Dis : Off J Ital Soc Gastroenterol Ital Assoc Study Liver 42:848–853CrossRef
109.
Ludwiczek O, Vannier E, Borggraefe I, Kaser A, Siegmund B, Dinarello CA, Tilg H (2004) Imbalance between interleukin-1 agonists and antagonists: relationship to severity of inflammatory bowel disease. Clin Exp Immunol 138:323–329PubMedPubMedCentralCrossRef
110.
Bauer C, Loher F, Dauer M, Mayer C, Lehr HA, Schonharting M, Hallwachs R, Endres S, Eigler A (2007) The ICE inhibitor pralnacasan prevents DSS-induced colitis in C57BL/6 mice and suppresses IP-10 mRNA but not TNF-alpha mRNA expression. Dig Dis Sci 52:1642–1652PubMedCrossRef
111.
Cominelli F, Nast CC, Duchini A, Lee M (1992) Recombinant interleukin-1 receptor antagonist blocks the proinflammatory activity of endogenous interleukin-1 in rabbit immune colitis. Gastroenterology 103:65–71PubMed
112.
Ferretti M, Casini-Raggi V, Pizarro TT, Eisenberg SP, Nast CC, Cominelli F (1994) Neutralization of endogenous IL-1 receptor antagonist exacerbates and prolongs inflammation in rabbit immune colitis. J Clin Invest 94:449–453PubMedPubMedCentralCrossRef
113.
Loher F, Bauer C, Landauer N, Schmall K, Siegmund B, Lehr HA, Dauer M, Schoenharting M, Endres S, Eigler A (2004) The interleukin-1 beta-converting enzyme inhibitor pralnacasan reduces dextran sulfate sodium-induced murine colitis and T helper 1 T-cell activation. J Pharmacol Exp Ther 308:583–590PubMedCrossRef
114.
Siegmund B, Lehr HA, Fantuzzi G, Dinarello CA (2001) IL-1 beta -converting enzyme (caspase-1) in intestinal inflammation. Proc Natl Acad Sci U S A 98:13249–13254PubMedPubMedCentralCrossRef
115.
Reuter BK, Pizarro TT (2004) Commentary: the role of the IL-18 system and other members of the IL-1R/TLR superfamily in innate mucosal immunity and the pathogenesis of inflammatory bowel disease: friend or foe? Eur J Immunol 34:2347–2355PubMedCrossRef
116.
117.
118.
Katsurano M, Niwa T, Yasui Y, Shigematsu Y, Yamashita S, Takeshima H, Lee MS, Kim YJ, Tanaka T, Ushijima T (2012) Early-stage formation of an epigenetic field defect in a mouse colitis model, and non-essential roles of T- and B-cells in DNA methylation induction. Oncogene 31:342–351PubMedCrossRef
119.
Gunter MJ, Canzian F, Landi S, Chanock SJ, Sinha R, Rothman N (2006) Inflammation-related gene polymorphisms and colorectal adenoma. Cancer Epidemiol Biomark Prev : Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol 15:1126–1131CrossRef
120.
Graziano F, Ruzzo A, Canestrari E, Loupakis F, Santini D, Rulli E, Humar B, Galluccio N, Bisonni R, Floriani I, Maltese P, Falcone A, Tonini G, Catalano V, Fontana A, Giustini L, Masi G, Vincenzi B, Alessandroni P, Magnani M (2009) Variations in the interleukin-1 receptor antagonist gene impact on survival of patients with advanced colorectal cancer. Pharmacogenomics J 9:78–84PubMedCrossRef
121.
Maeda S, Hsu LC, Liu H, Bankston LA, Iimura M, Kagnoff MF, Eckmann L, Karin M (2005) Nod2 mutation in Crohn’s disease potentiates NF-kappaB activity and IL-1beta processing. Science 307:734–738PubMedCrossRef
122.
Elinav E, Henao-Mejia J, Flavell RA (2013) Integrative inflammasome activity in the regulation of intestinal mucosal immune responses. Mucosal Immunol 6:4–13PubMedCrossRef
123.
Gagliani N, Palm NW, de Zoete MR, Flavell RA (2014) Inflammasomes and intestinal homeostasis: regulating and connecting infection, inflammation and the microbiota. Int Immunol 26:495–499PubMedPubMedCentralCrossRef
124.
Lissner D, Siegmund B (2011) The multifaceted role of the inflammasome in inflammatory bowel diseases. TheScientificWorldJOURNAL 11:1536–1547PubMedCrossRef
125.
Nunes T, de Souza HS (2013) Inflammasome in intestinal inflammation and cancer. Mediat Inflamm 2013:654963CrossRef
126.
Murthy SN, Cooper HS, Shim H, Shah RS, Ibrahim SA, Sedergran DJ (1993) Treatment of dextran sulfate sodium-induced murine colitis by intracolonic cyclosporin. Dig Dis Sci 38:1722–1734PubMedCrossRef
127.
Allen IC, TeKippe EM, Woodford RM, Uronis JM, Holl EK, Rogers AB, Herfarth HH, Jobin C, Ting JP (2010) The NLRP3 inflammasome functions as a negative regulator of tumorigenesis during colitis-associated cancer. J Exp Med 207:1045–1056PubMedPubMedCentralCrossRef
128.
Hu B, Elinav E, Huber S, Booth CJ, Strowig T, Jin C, Eisenbarth SC, Flavell RA (2010) Inflammation-induced tumorigenesis in the colon is regulated by caspase-1 and NLRC4. Proc Natl Acad Sci U S A 107:21635–21640PubMedPubMedCentralCrossRef
129.
Zaki MH, Boyd KL, Vogel P, Kastan MB, Lamkanfi M, Kanneganti TD (2010) The NLRP3 inflammasome protects against loss of epithelial integrity and mortality during experimental colitis. Immunity 32:379–391PubMedPubMedCentralCrossRef
130.
Hirota SA, Ng J, Lueng A, Khajah M, Parhar K, Li Y, Lam V, Potentier MS, Ng K, Bawa M, McCafferty DM, Rioux KP, Ghosh S, Xavier RJ, Colgan SP, Tschopp J, Muruve D, MacDonald JA, Beck PL (2011) NLRP3 inflammasome plays a key role in the regulation of intestinal homeostasis. Inflamm Bowel Dis 17:1359–1372PubMedPubMedCentralCrossRef
131.
Elinav E, Strowig T, Kau AL, Henao-Mejia J, Thaiss CA, Booth CJ, Peaper DR, Bertin J, Eisenbarth SC, Gordon JI, Flavell RA (2011) NLRP6 inflammasome regulates colonic microbial ecology and risk for colitis. Cell 145:745–757PubMedPubMedCentralCrossRef
132.
Dupaul-Chicoine J, Yeretssian G, Doiron K, Bergstrom KS, McIntire CR, LeBlanc PM, Meunier C, Turbide C, Gros P, Beauchemin N, Vallance BA, Saleh M (2010) Control of intestinal homeostasis, colitis, and colitis-associated colorectal cancer by the inflammatory caspases. Immunity 32:367–378PubMedCrossRef
133.
Salcedo R, Worschech A, Cardone M, Jones Y, Gyulai Z, Dai RM, Wang E, Ma W, Haines D, O’HUigin C, Marincola FM, Trinchieri G (2010) MyD88-mediated signaling prevents development of adenocarcinomas of the colon: role of interleukin 18. J Exp Med 207:1625–1636PubMedPubMedCentralCrossRef
134.
Wlodarska M, Thaiss CA, Nowarski R, Henao-Mejia J, Zhang JP, Brown EM, Frankel G, Levy M, Katz MN, Philbrick WM, Elinav E, Finlay BB, Flavell RA (2014) NLRP6 inflammasome orchestrates the colonic host-microbial interface by regulating goblet cell mucus secretion. Cell 156:1045–1059PubMedPubMedCentralCrossRef
135.
Bauer C, Duewell P, Mayer C, Lehr HA, Fitzgerald KA, Dauer M, Tschopp J, Endres S, Latz E, Schnurr M (2010) Colitis induced in mice with dextran sulfate sodium (DSS) is mediated by the NLRP3 inflammasome. Gut 59:1192–1199PubMedCrossRef
136.
Pizarro TT, Michie MH, Bentz M, Woraratanadharm J, Smith MF Jr, Foley E, Moskaluk CA, Bickston SJ, Cominelli F (1999) IL-18, a novel immunoregulatory cytokine, is up-regulated in Crohn’s disease: expression and localization in intestinal mucosal cells. J Immunol 162:6829–6835PubMed
137.
138.
Huber S, Gagliani N, Zenewicz LA, Huber FJ, Bosurgi L, Hu B, Hedl M, Zhang W, O’Connor W Jr, Murphy AJ, Valenzuela DM, Yancopoulos GD, Booth CJ, Cho JH, Ouyang W, Abraham C, Flavell RA (2012) IL-22BP is regulated by the inflammasome and modulates tumorigenesis in the intestine. Nature 491:259–263PubMedPubMedCentralCrossRef
139.
Munoz M, Eidenschenk C, Ota N, Wong K, Lohmann U, Kuhl AA, Wang X, Manzanillo P, Li Y, Rutz S, Zheng Y, Diehl L, Kayagaki N, van Lookeren-Campagne M, Liesenfeld O, Heimesaat M, Ouyang W (2015) Interleukin-22 induces interleukin-18 expression from epithelial cells during intestinal infection. Immunity 42:321–331PubMedCrossRef
140.
Koltsova EK, Grivennikov SI (2014) IL-22 gets to the stem of colorectal cancer. Immunity 40:639–641PubMedCrossRef
141.
Kryczek I, Lin Y, Nagarsheth N, Peng D, Zhao L, Zhao E, Vatan L, Szeliga W, Dou Y, Owens S, Zgodzinski W, Majewski M, Wallner G, Fang J, Huang E, Zou W (2014) IL-22(+)CD4(+) T cells promote colorectal cancer stemness via STAT3 transcription factor activation and induction of the methyltransferase DOT1L. Immunity 40:772–784PubMedPubMedCentralCrossRef
142.
Bauer C, Duewell P, Lehr HA, Endres S, Schnurr M (2012) Protective and aggravating effects of Nlrp3 inflammasome activation in IBD models: influence of genetic and environmental factors. Dig Dis 30(Suppl 1):82–90PubMedCrossRef
143.
Lebeis SL, Powell KR, Merlin D, Sherman MA, Kalman D (2009) Interleukin-1 receptor signaling protects mice from lethal intestinal damage caused by the attaching and effacing pathogen Citrobacter rodentium. Infect Immun 77:604–614PubMedPubMedCentralCrossRef
144.
Bersudsky M, Luski L, Fishman D, White RM, Ziv-Sokolovskaya N, Dotan S, Rider P, Kaplanov I, Aychek T, Dinarello CA, Apte RN, Voronov E (2014) Non-redundant properties of IL-1alpha and IL-1beta during acute colon inflammation in mice. Gut 63:598–609PubMedCrossRef
145.
Suwara MI, Green NJ, Borthwick LA, Mann J, Mayer-Barber KD, Barron L, Corris PA, Farrow SN, Wynn TA, Fisher AJ, Mann DA (2014) IL-1alpha released from damaged epithelial cells is sufficient and essential to trigger inflammatory responses in human lung fibroblasts. Mucosal Immunol 7:684–693PubMedPubMedCentralCrossRef
146.
Scarpa M, Kessler S, Sadler T, West G, Homer C, McDonald C, de la Motte C, Fiocchi C, Stylianou E (2015) The epithelial danger signal IL-1alpha is a potent activator of fibroblasts and reactivator of intestinal inflammation. Am J Pathol 185:1624–1637PubMedCrossRef
147.
Xiao H, Gulen MF, Qin J, Yao J, Bulek K, Kish D, Altuntas CZ, Wald D, Ma C, Zhou H, Tuohy VK, Fairchild RL, de la Motte C, Cua D, Vallance BA, Li X (2007) The Toll-interleukin-1 receptor member SIGIRR regulates colonic epithelial homeostasis, inflammation, and tumorigenesis. Immunity 26:461–475PubMedCrossRef
148.
149.
Shaw MH, Kamada N, Kim YG, Nunez G (2012) Microbiota-induced IL-1beta, but not IL-6, is critical for the development of steady-state TH17 cells in the intestine. J Exp Med 209:251–258PubMedPubMedCentralCrossRef
150.
151.
152.
Hasegawa M, Kamada N, Jiao Y, Liu MZ, Nunez G, Inohara N (2012) Protective role of commensals against Clostridium difficile infection via an IL-1beta-mediated positive-feedback loop. J Immunol 189:3085–3091PubMedPubMedCentralCrossRef
153.
Dzutsev A, Goldszmid RS, Viaud S, Zitvogel L, Trinchieri G (2015) The role of the microbiota in inflammation, carcinogenesis, and cancer therapy. Eur J Immunol 45:17–31PubMedCrossRef
154.
155.
Seo SU, Kamada N, Munoz-Planillo R, Kim YG, Kim D, Koizumi Y, Hasegawa M, Himpsl SD, Browne HP, Lawley TD, Mobley HL, Inohara N, Nunez G (2015) Distinct commensals induce interleukin-1beta via NLRP3 inflammasome in inflammatory monocytes to promote intestinal inflammation in response to injury. Immunity 42:744–755PubMedCrossRef
Metadata
Title
IL-1 in Colon Inflammation, Colon Carcinogenesis and Invasiveness of Colon Cancer
Authors
Elena Voronov
Ron N. Apte
Publication date
01-12-2015
Publisher
Springer Netherlands
Published in
Cancer Microenvironment / Issue 3/2015
Print ISSN: 1875-2292
Electronic ISSN: 1875-2284
DOI
https://doi.org/10.1007/s12307-015-0177-7

Other articles of this Issue 3/2015

Cancer Microenvironment 3/2015 Go to the issue

Original Article

The Multifaceted Roles Neutrophils Play in the Tumor Microenvironment

OriginalPaper

Preface

Original Paper

Tumour Microenvironment: Overview with an Emphasis on the Colorectal Liver Metastasis Pathway

Original Paper

The Role of Mast Cells in Molding the Tumor Microenvironment

Original Article

Stroma as an Active Player in the Development of the Tumor Microenvironment

Original Paper

Clinical Impact of Regulatory T cells (Treg) in Cancer and HIV
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits